Beta Bionics (NASDAQ:BBNX) Stock Price Down 7.1% - Here's Why

Beta Bionics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Beta Bionics shares fell 7.1% in Thursday mid-day trading, from a prior close of $14.33 to about $13.31; trading volume was 54% below its average.
  • Analysts maintain a consensus “Moderate Buy” rating, with an average price target of $23.69.
  • The company reported quarterly revenue of $35.51 million and a loss of $0.52 per share, narrowly beating analysts’ loss estimate of $0.53; it remains unprofitable.
  • Five stocks to consider instead of Beta Bionics.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) shares were down 7.1% during mid-day trading on Thursday. The company traded as low as $13.05 and last traded at $13.3120. Approximately 544,883 shares traded hands during mid-day trading, a decline of 54% from the average session volume of 1,172,508 shares. The stock had previously closed at $14.33.

Wall Street Analyst Weigh In

BBNX has been the topic of several analyst reports. Barclays began coverage on Beta Bionics in a report on Tuesday, October 6th. They issued an "overweight" rating and a $30.00 target price on the stock. Wells Fargo & Company began coverage on shares of Beta Bionics in a research note on Wednesday, September 23rd. They set an "overweight" rating and a $28.00 price target for the company. William Blair initiated coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a "market perform" rating on the stock. Robert W. Baird upped their price target on Beta Bionics from $14.00 to $16.00 and gave the company a "neutral" rating in a research report on Tuesday, September 15th. Finally, Bank of America increased their price objective on Beta Bionics from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.69.

Get Our Latest Analysis on Beta Bionics

Beta Bionics Stock Performance

The company has a market capitalization of $724.44 million, a PE ratio of -7.22 and a beta of 3.44. The business's 50-day moving average is $18.23 and its 200-day moving average is $14.87.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.01. The business had revenue of $35.51 million during the quarter. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. Analysts expect that Beta Bionics, Inc. will post -2.04 EPS for the current year.

Insider Activity

In other Beta Bionics news, insider Mike Mensinger sold 2,650 shares of the stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $22.00, for a total value of $58,300.00. Following the completion of the sale, the insider directly owned 174,740 shares in the company, valued at approximately $3,844,280. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Stephen Feider sold 6,675 shares of the business's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $127,559.25. Following the sale, the chief financial officer owned 159,378 shares in the company, valued at approximately $3,045,713.58. The trade was a 4.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 103,844 shares of company stock valued at $2,026,928. Insiders own 5.30% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new position in shares of Beta Bionics in the 2nd quarter valued at $62,000. The Manufacturers Life Insurance Company acquired a new position in shares of Beta Bionics during the second quarter worth about $172,000. 49 Wealth Management LLC purchased a new stake in shares of Beta Bionics during the 3rd quarter worth $260,000. Ieq Capital LLC purchased a new stake in Beta Bionics during the 2nd quarter worth about $229,000. Finally, Quantbot Technologies LP purchased a new position in Beta Bionics in the second quarter valued at approximately $264,000.

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user's body weight and adjusts insulin delivery based on glucose readings.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Beta Bionics Right Now?

Before you consider Beta Bionics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.

While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines